Literature DB >> 33090338

Relationships between cystatin C- and creatinine-based eGFR in Japanese rural community- dwelling older adults with sarcopenia.

Hiroshi Kusunoki1, Shotaro Tsuji2, Tomoyuki Kusukawa2, Yosuke Wada3,4, Kayoko Tamaki1, Koutatsu Nagai5, Masako Itoh5, Kyoko Sano5, Manabu Amano6, Hatsuo Maeda6, Hideyuki Sugita7, Yoko Hasegawa7,8, Hiromitsu Kishimoto7, Soji Shimomura3, Ken Shinmura9,10.   

Abstract

BACKGROUND: Sarcopenia is prevalent in patients with chronic kidney disease (CKD). The indices of physical function, such as grip power and gait speed, decreased according to the decline in the estimated glomerular filtration rate (eGFR).
METHODS: We examined the relationships between cystatin C-based GFR (eGFRcys), creatinine-based GFR (eGFRcre), their ratio (eGFRcys/eGFRcre) and sarcopenia in community-dwelling older adults in Japan. This cross-sectional study included 302 men aged 73.9 ± 6.2 years and 647 women aged 72.9 ± 5.8 years from a rural area in Hyogo Prefecture, Japan. eGFRcys and eGFRcre were simultaneously measured, and sarcopenia based on the Asia Working Group for Sarcopenia (AWGS) 2019 criteria was evaluated.
RESULTS: eGFRcys and the eGFRcys/eGFRcre ratio were significantly correlated with grip power and gait speed (p < 0.001). The eGFRcys/eGFRcre ratio was also correlated with skeletal muscle mass index (SMI) (p < 0.01). Univariate logistic regression analysis showed eGFRcys and eGFRcys/eGFRcre ratio but not eGFRcre were associated with sarcopenia (p < 0.01). The presence of low eGFRcys (CKDcys) and low eGFRcys/eGFRcre ratio (< 1.0) but not that of low eGFRcre (CKDcre) were associated with sarcopenia (p < 0.01). In the multivariate logistic regression analysis, when the eGFRcys/eGFRcre ratio was added as a covariate to the basic model, it was significantly associated with sarcopenia in women (p < 0.05). Moreover, low eGFRcys/eGFRcre ratio (< 1.0) was associated with a higher risk of sarcopenia in men (p < 0.01).
CONCLUSION: In conclusion, CKDcys but not CKDcre is associated with sarcopenia. A lower eGFRcys/eGFRcre ratio may be a practical screening marker of sarcopenia in community-dwelling older adults.

Entities:  

Keywords:  AWGS; Cystatin C; Sarcopenia; Skeletal muscle mass index (SMI); eGFR

Year:  2020        PMID: 33090338      PMCID: PMC7925493          DOI: 10.1007/s10157-020-01981-x

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  1 in total

1.  Indices calculated by serum creatinine and cystatin C as predictors of liver damage, muscle strength and sarcopenia in liver disease.

Authors:  Tatsuki Ichikawa; Hisamitsu Miyaaki; Satoshi Miuma; Yasuhide Motoyoshi; Mio Yamashima; Shinobu Yamamichi; Makiko Koike; Youichi Takahashi; Tetsurou Honda; Hiroyuki Yajima; Ryouhei Uehara; Naoyuki Hino; Ryousuke Hirata; Naota Taura; Kazuhiko Nakao
Journal:  Biomed Rep       Date:  2020-01-24
  1 in total
  4 in total

1.  Comparison of Creatinine and Cystatin C to Estimate Renal Function in Geriatric and Frail Patients.

Authors:  Erik Dahlén; Linda Björkhem-Bergman
Journal:  Life (Basel)       Date:  2022-06-07

2.  A Novel Application of Serum Creatinine and Cystatin C to Predict Sarcopenia in Advanced CKD.

Authors:  Yu-Li Lin; Chih-Hsien Wang; I-Chen Chang; Bang-Gee Hsu
Journal:  Front Nutr       Date:  2022-02-25

3.  Relationships between cystatin C and creatinine-based eGFR with low tongue pressure in Japanese rural community-dwelling older adults.

Authors:  Hiroshi Kusunoki; Yoko Hasegawa; Shotaro Tsuji; Yosuke Wada; Kayoko Tamaki; Koutatsu Nagai; Takara Mori; Ryota Matsuzawa; Hiromitsu Kishimoto; Hideo Shimizu; Ken Shinmura
Journal:  Clin Exp Dent Res       Date:  2022-06-24

4.  Estimation of kidney function in patients with primary neuromuscular diseases: is serum cystatin C a better marker of kidney function than creatinine?

Authors:  Annika Aldenbratt; Christopher Lindberg; Elias Johannesson; Ola Hammarsten; Maria K Svensson
Journal:  J Nephrol       Date:  2021-08-05       Impact factor: 3.902

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.